Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X

Find Tinostamustine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Tinostamustine
Also known as: Edo-s101, 1236199-60-2, Minomustine, Edo-s 101, Edo-s-101, Tinostamustine [usan]
Molecular Formula
C19H28Cl2N4O2
Molecular Weight
415.4  g/mol
InChI Key
GISXTRIGVCKQBX-UHFFFAOYSA-N
FDA UNII
29DKI2H2NY

Tinostamustine is an alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.
1 2D Structure

Tinostamustine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide
2.1.2 InChI
InChI=1S/C19H28Cl2N4O2/c1-24-17-9-8-15(25(12-10-20)13-11-21)14-16(17)22-18(24)6-4-2-3-5-7-19(26)23-27/h8-9,14,27H,2-7,10-13H2,1H3,(H,23,26)
2.1.3 InChI Key
GISXTRIGVCKQBX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO
2.2 Other Identifiers
2.2.1 UNII
29DKI2H2NY
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Edo-s101

2.3.2 Depositor-Supplied Synonyms

1. Edo-s101

2. 1236199-60-2

3. Minomustine

4. Edo-s 101

5. Edo-s-101

6. Tinostamustine [usan]

7. Tinostamustine(edo-s101)

8. 29dki2h2ny

9. 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzo[d]imidazol-2-yl)-n-hydroxyheptanamide

10. 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-n-hydroxyheptanamide

11. 1h-benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-n-hydroxy-1-methyl-

12. 1h-benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-n-hydroxy-1-methyl-

13. Starbld0018955

14. Unii-29dki2h2ny

15. Tinostamustine (usan/inn)

16. Tinostamustine [inn]

17. Schembl7915449

18. Tinostamustine [who-dd]

19. Chembl3989941

20. Bcp20331

21. Ex-a1322

22. Bdbm50569838

23. Zinc68244536

24. Cs-6484

25. Db15147

26. Sb19172

27. Be170657

28. Hy-101780

29. S8769

30. D11182

31. E76854

32. 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzimidazol-2-yl)-n-hydroxyheptanamide

2.4 Create Date
2010-08-09
3 Chemical and Physical Properties
Molecular Weight 415.4 g/mol
Molecular Formula C19H28Cl2N4O2
XLogP33.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count12
Exact Mass414.1589315 g/mol
Monoisotopic Mass414.1589315 g/mol
Topological Polar Surface Area70.4 Ų
Heavy Atom Count27
Formal Charge0
Complexity438
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY